skip to main content

NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerNSCLCSCE Medical Oncology

A patient with KRAS G12C-mutated metastatic NSCLC received platinum chemotherapy and anti-PD-1 therapy and now has progression. Which statement most accurately reflects the published NICE TA781 position for sotorasib?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Managed-access sotorasib after platinum or PD-1/PD-L1 treatment

The published TA781 recommendation is for KRAS G12C-positive locally advanced or metastatic NSCLC after progression on or intolerance of platinum chemotherapy or anti-PD-1/PD-L1 treatment, subject to managed-access conditions. It is not first line, not for KRAS wild type or small-cell cancer, and does not require osimertinib.

Reference: NICE TA781: sotorasib for previously treated KRAS G12C NSCLC. https://www.nice.org.uk/guidance/ta781/chapter/1-Recommendations